Cubist Systematic Strategies’s TG Therapeutics TGTX Stock Holding History

Cubist Systematic Strategies’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,500	Closed	-$414K	–	3514
2025 Q1	$414K	Buy	10,500 +400	+4%	+$13.5K	﹤0.01%	2243
2024 Q4	$304K	Buy	10,100 +2,700	+36%	+$77.5K	﹤0.01%	2404
2024 Q3	$173K	Buy	+7,400	New	+$162K	﹤0.01%	2606
2024 Q2	–	Sell	-23,000	Closed	-$350K	–	3996
2024 Q1	$350K	Buy	23,000 +11,300	+97%	+$180K	﹤0.01%	2813
2023 Q4	$200K	Buy	+11,700	New	+$136K	﹤0.01%	3005

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cubist Systematic Strategies's TGTX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its TG Therapeutics (TGTX) stake by 58% in Q3 2025, selling an estimated $4.66M and leaving 102,548 shares worth $3.7M. The position accounts for 0.02% of the portfolio, ranked #1163.

Cubist Systematic Strategies first reported a position in TGTX in Q4 2014 and has held it in 25 quarters since. The position peaked at $12.1M in Q2 2024. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

Cubist Systematic Strategies held 102,548 shares of TG Therapeutics worth $3.7M as of Q3 2025.
Cubist Systematic Strategies sold 141,438 TG Therapeutics shares in Q3 2025, an estimated $4.66M.
TG Therapeutics made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1163 holding.
Cubist Systematic Strategies first reported a position in TG Therapeutics in Q4 2014 and has held it in 25 quarters since.
Cubist Systematic Strategies's TG Therapeutics position peaked at $12.1M in Q2 2024.
354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.